Abnormal activation of the Akt-GSK3β signaling pathway in peripheral blood T cells from patients with systemic lupus erythematosus

Cell Cycle

Volumn 8, Issue 17, 2009, Pages 2789-2793

  Tang, Hongfeng ^a   Tan, Guozhen ^a   Guo, Qing ^a   Pang, Ruiping ^b   Zeng, Fanqin ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Akt; Cell cycle; GSK3 ; Systemic lupus erythematosus (SLE); T lymphocytes

Indexed keywords

2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; GLYCOGEN SYNTHASE KINASE 3; LITHIUM CHLORIDE; PHYTOHEMAGGLUTININ; PROTEIN GSK3 BETA; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ARTICLE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; KIDNEY DISEASE; LYMPHOCYTE; PHOSPHORYLATION; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; UPREGULATION;

EID: 69749102963     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.8.17.9446     Document Type: Article

References (23)

1. Kotzin BL. Systemic lupus erythematosus. Cell 1996; 85:303-306
2. Eilat D, Naparstek Y. Anti-DNA autoantibodies: a puzzle of autoimmune phenomena. Immunol Today 1999; 20:339-342 (Pubitemid 29356425)
3. Singh RR, Hahn BH. Reciprocal T-B determinant spreading develops spontaneously in murine lupus: implications for pathogenesis. Immunol Rev 1998; 164:201-208
4. Chatham WW, Kimberly RP. Treatment of lupus with corticosteroids. Lupus 2001; 10:140-147
5. 1-phase progression. Genes Dev 1999; 13:1501-1512
6. Sherr CJ. Cancer cell cycles. Science 1996; 274:1671-1676
7. King PD. Lupus-like autoimmunity caused by defects in T-cell signal transduction. Curr Opin Investig Drugs 2004; 5:517-523
8. Niculescu F, Nguyen P, Niculescu T, Rus H, Rus V, Via CS. Pathogenic T cells in murine lupus exhibit spontaneous signaling activity through phosphatidylinositol 3-kinase and mitogen-activated protein kinase pathways. Arthritis Rheum 2003; 48:1071-1079 (Pubitemid 36418250)
9. Barber DF, Bartolome A, Hernandez C, Flores JM, Redondo C, Fernandez-Arias C, et al. PI3Kγinhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus. Nat Med 2005; 11:933-935 (Pubitemid 41294437)
10. Petri M. Review of classification criteria for systemic lupus erythematosus. Rheum Dis Clin North Am 2005; 31:245-254 (Pubitemid 40732487)
11. Tokano Y, Morimoto S, Hishikawa T, Murashima A, Abe M, Sekigawa I, et al. Subsets of activated T cells in patients with systemic lupus erythematosus: the relation to cell cycle. Scand J Rheumatol 1997; 26:37-42. (Pubitemid 27105159)
12. Yamauchi A, Bloom ET. Control of cell cycle progression in human natural killer cells through redox regulation of expression and phosphorylation of retinoblastoma gene product protein. Blood 1997; 89:4092-4099 (Pubitemid 27220956)
13. Santiago-Raber ML, Lawson BR, Dummer W, Barnhouse M, Koundouris S, Wilson CB, et al. Role of cyclin kinase inhibitor p21 in systemic autoimmunity. J Immunol 2001; 167:4067-4074 (Pubitemid 32910854)
14. Balomenos D, Martinez-A C. Cell cycle regulation in immunity, tolerance and autoimmunity. Immunol Today 2000; 21:551-555
15. Balomenos D, Martin-Caballero J, Garcia MI, Prieto I, Flores JM, Serrano M, Martínez-A C. The cell cycle inhibitor p21 controls T-cell proliferation and sex-linked lupus development. Nat Med 2000; 6:171-176 (Pubitemid 30082361)
16. Jones RG, Parsons M, Bonnard M, Chan VS, Yeh WC, Woodgett JR, Ohashi PS. Protein kinase B regulates T lymphocyte survival, nuclear factor B activation, and Bcl-X(L) levels in vivo. J Exp Med 2000; 191:1721-1734
17. King CG, Kobayashi T, Cejas PJ, Kim T, Yoon K, Kim GK, et al. TRAF6 is a T cell-intrinsic negative regulator required for the maintenance of immune homeostasis. Nat Med 2006; 12:1088-1092 (Pubitemid 44353391)
18. Borlado LR, Redondo C, Alvarez B, Jimenez C, Criado LM, Flores J, et al. Increased phosphoinositide 3-kinase activity induces a lymphoproliferative disorder and contributes to tumor generation in vivo. FASEB J 2000; 14:895-903. (Pubitemid 30241666)
19. Beurel E, Kornprobst M, Blivet-Van Eggelpoel MJ, Ruiz-Ruiz C, Cadoret A, Capeau J, Desbois-Mouthon C. GSK-3beta inhibition by lithium confers resistance to chemotherapy- induced apoptosis through the repression of CD95 (Fas/APO-1) expression. Exp Cell Res 2004; 300:354-364 (Pubitemid 39314425)
20. Liu S, Yu S, Hasegawa Y, Lapushin R, Xu HJ, Woodgett JR, et al. Glycogen synthase kinase 3beta is a negative regulator of growth factor-induced activation of the c-Jun N-terminal kinase. J Biol Chem 2004; 279:51075-51081 (Pubitemid 40017849)
21. Pang RP, Zhou JG, Zeng ZR, Li XY, Chen W, Chen MH, Hu PJ. Celecoxib induces apoptosis in COX-2 deficient human gastric cancer cells through Akt/GSK3b/NAG-1 pathway. Cancer Letters 2007; 251:268-277 (Pubitemid 46671612)
22. Welsh GI, Miyamoto S, Price NT, Safer B, Proud CG. T-cell activation leads to rapid stimulation of translation initiation factor eIF2B and inactivation of glycogen synthase kinase-3. J Biol Chem 1996; 271:11410-11413 (Pubitemid 26155980)
23. Sengupta S, Jayaraman P, Chilton PM, Casella CR, Mitchell TC. Unrestrained Glycogen Synthase Kinase-3beta Activity Leads to Activated T Cell Death and Can Be Inhibited by Natural Adjuvant. J Immunol 2007; 178:6083-6091 (Pubitemid 46717388)